![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, May 11, 2024 8:40:27 AM
Reiterates HC Wainwright & Co.: Buy to Buy 5/10/2024
Iovance Biotherapeutics Poised for Growth: Analyst Reiterates Buy Rating Amid Strong Q1 Performance and Promising Clinical Advancements
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Iovance Biotherapeutics (IOVA – Research Report), with a price target of $32.00.
Joseph Pantginis has given his Buy rating due to a combination of factors that suggest a strong potential for Iovance Biotherapeutics’ growth and profitability. The company’s recent earnings report for the first quarter of 2024 surpassed expectations with a lower-than-anticipated loss per share and showed a promising cash position. Pantginis notes the importance of Proleukin sales, which are now projected to substantially contribute to Iovance’s revenue throughout the year. Additionally, the analyst sees the enrollment progress of AMTAGVI therapy, with over 100 patients already enrolled and 60 more in the pipeline, as a sign of strong launch momentum that is expected to carry forward, particularly as the company aims to expand into global markets
https://markets.businessinsider.com/news/stocks/iovance-biotherapeutics-poised-for-growth-analyst-reiterates-buy-rating-amid-strong-q1-performance-and-promising-clinical-advancements-1033363090
The first quarter of 2024 was transformative for Iovance. It included:
Commercialization: Following FDA approval, Amtagvi's launch progressed rapidly, with over 100 patients enrolled via more than 40 authorized treatment centers.
Global strategy: Plans for regulatory submissions in Europe, Canada, and Australia reflect Iovance's ambition for global reach.
R&D drive: The ongoing Phase 3 TILVANCE-301 trial and other studies fortify the pipeline, emphasizing the strategic focus on TIL cell therapies.
Financial performance: Despite lower-than-expected revenue, strategic investments in R&D and commercialization are shaping long-term prospects.
Iovance also produces a melanoma cancer drug aldesleukin (originally approved for use back in the late 1990s) under the brand name Proleukin. Iovance is now recognizing all Proleukin revenues for commercial and clinical use and recently began significant sales to distributors. Iovance completed the transfer of marketing authorizations in Q1 and began distribution of Proleukin. Beginning in Q2, Iovance expects to recognize significant incremental revenues for Proleukin as part of the Amtagvi treatment regimen.
https://www.fool.com/data-news/2024/05/10/iovance-biotherapeutics-q1-revenue-falls-short/
All my posts on the site are to be considered opinions.
Readers determine the veracity of the posts they read and the credibility of other Users
Recent IOVA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 11:56:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 11:54:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 11:53:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 11:52:10 PM
- Iovance Biotherapeutics to Present at Upcoming Conferences • GlobeNewswire Inc. • 09/03/2024 09:00:18 PM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 08/16/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 09:16:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 09:10:32 PM
- Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024 • GlobeNewswire Inc. • 08/08/2024 08:01:32 PM
- Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024 • GlobeNewswire Inc. • 07/29/2024 08:01:00 PM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 07/19/2024 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/18/2024 12:01:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/18/2024 12:01:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/18/2024 12:00:18 AM
- Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma • GlobeNewswire Inc. • 06/28/2024 11:00:00 AM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 06/21/2024 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 10:03:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 10:00:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 09:15:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 12:07:04 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 12:05:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 12:04:19 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 12:01:02 PM
- Iovance Biotherapeutics to Present at Upcoming Conferences and Events • GlobeNewswire Inc. • 05/24/2024 08:01:00 PM
- Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting • GlobeNewswire Inc. • 05/23/2024 09:00:00 PM
FEATURED Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • Sep 10, 2024 11:00 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM
Nightfood Holdings Inc. Completes Major Step on Uplist Journey by Closing Strategic All-Stock Acquisition of CarryoutSupplies.com • NGTF • Sep 10, 2024 8:15 AM
Element79 Gold Corp. Announces Sale of 100% Interest in Elder Creek, North Mill Creek, and Elephant Projects to 1472886 B.C. Ltd. • ELEM • Sep 9, 2024 9:34 AM
North Bay Resources Commences Gold Shipments, Fran Gold Project, British Columbia; Enters Taber Gold Mine JV, Sierra County, California • NBRI • Sep 9, 2024 9:15 AM
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM